Portal de Periódicos da CAPES

Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

1999; Elsevier BV; Volume: 83; Issue: 3 Linguagem: Inglês

10.1016/s0002-9149(98)00886-8

1879-1913

Joseph L. Blackshear, Miguel Zabalgoitia, Gregory D. Pennock, Paul E. Fenster, Richard Strauß, Jonathan L. Halperin, Richard Asinger, Lesly A. Pearce,

Cardiac Imaging and Diagnostics

In this report we describe the outcome of patients who participated in the Stroke Prevention and Atrial Fibrillation (SPAF) III randomized trial with atrial fibrillation (AF) who had aortic atherosclerotic plaque identified by transesophageal echocardiography (TEE) within 3 months of enrollment. These data represent the largest reported experience of patients with well-defined aortic plaque in whom treatment assignment included conventional warfarin (international normalized ratio [INR] 2.0 to 3.0).